Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VYVGART HYTRULO vs VYVGART
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a combination of efgartigimod alfa, a neonatal Fc receptor (Fc Rn) blocker, and hyaluronidase, an endoglycosidase that enhances subcutaneous fluid dispersion. Efgartigimod alfa binds to Fc Rn, reducing recycling of Ig G and lowering plasma Ig G levels, including pathogenic autoantibodies.
Neonatal Fc receptor (Fc Rn) antagonist; reduces Ig G recycling, lowering pathogenic Ig G autoantibody levels.
Treatment of generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor (ACh R) antibody positive
Treatment of generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor (ACh R) antibody positive
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) subcutaneous injection: For adult patients with generalized myasthenia gravis (g MG) who are anti-ACh R antibody positive, the recommended dosage is 1,008 mg efgartigimod alfa and 12,000 units hyaluronidase administered subcutaneously once weekly for 4 weeks. Subsequent cycles may be initiated based on clinical response, with at least one week between cycles; the safety and efficacy of initiating subsequent cycles more frequently than every 6 weeks have not been established.
10 mg/kg intravenously over 1 hour, once weekly for 4 weeks (4 doses total), then 10 mg/kg intravenously over 1 hour every 2 weeks starting at week 5.
The terminal elimination half-life of efgartigimod alfa is approximately 14 days (range 12-18 days) following subcutaneous administration. This supports a dosing interval of once weekly for the initial cycle and every 2-4 weeks for maintenance.
Terminal half-life is approximately 80-120 hours (mean ~4 days). This supports a dosing interval of every 2 weeks after the initial weekly loading phase.
No dose adjustment is recommended for patients with mild to moderate renal impairment (estimated GFR ≥30 m L/min/1.73 m²). The effect of severe renal impairment (GFR <30 m L/min/1.73 m²) on the pharmacokinetics of efgartigimod alfa is unknown; use in such patients is not recommended.
No dose adjustment required for mild to moderate renal impairment (e GFR >= 30 m L/min/1.73 m²). Not studied in severe renal impairment (e GFR < 30 m L/min/1.73 m²) or end-stage renal disease; use not recommended.
None
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a neonatal Fc receptor antagonist. There are no adequate human data on use in pregnant women to inform a drug-associated risk of major birth defects or miscarriage. In animal reproduction studies, no adverse developmental outcomes were observed with subcutaneous administration of efgartigimod alfa during organogenesis in rabbits at doses up to 5 times the maximum recommended human dose (MRHD) based on AUC. However, hyaluronidase has been shown to cause fetal skeletal malformations in mice at high doses. Based on mechanism of action, efgartigimod alfa may reduce maternal Ig G levels and potentially impair maternal immunity to infections. During the second and third trimesters, Ig G is actively transferred across the placenta, and efgartigimod alfa may reduce this transfer, potentially affecting fetal/infant immune defense. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a neonatal Fc receptor (Fc Rn) blocker indicated for generalized myasthenia gravis (g MG) in ACh R antibody-positive adults. Administer as subcutaneous injection over 30-90 seconds in the abdomen (avoid 2-inch area around navel). Rotate injection sites. Premedication not required but monitor for hypersensitivity reactions. Contraindicated in patients with active hepatitis B infection due to potential reactivation. Monitor for infections; do not administer live vaccines during treatment. Assess baseline hepatitis B and tuberculosis screening before initiation.
VYVGART (efgartigimod alfa-fcab) is a neonatal Fc receptor (Fc Rn) antagonist approved for generalized myasthenia gravis (g MG) in ACh R antibody-positive patients. Monitor for infections due to Ig G reduction; administer IV over 1 hour weekly for 4 weeks. Consider Pneumocystis jirovecii prophylaxis if used with immunosuppressants. Not for myasthenic crisis.
No interactions on record
No interactions on record
Common clinical questions about VYVGART HYTRULO vs VYVGART, answered by our medical review team.
VYVGART HYTRULO is a FcRn Antagonist that works by VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a combination of efgartigimod alfa, a neonatal Fc receptor (Fc Rn) blocker, and hyaluronidase, an endoglycosidase that enhances subcutaneous fluid dispersion. Efgartigimod alfa binds to Fc Rn, reducing recycling of Ig G and lowering plasma Ig G levels, including pathogenic autoantibodies.. VYVGART is a FcRn Antagonist that works by Neonatal Fc receptor (Fc Rn) antagonist; reduces Ig G recycling, lowering pathogenic Ig G autoantibody levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VYVGART HYTRULO and VYVGART depend on the specific clinical indication. These are both FcRn Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VYVGART HYTRULO is: VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) subcutaneous injection: For adult patients with generalized myasthenia gravis (g MG) who are anti-ACh R antibody positive, the recommended dosage is 1,008 mg efgartigimod alfa and 12,000 units hyaluronidase administered subcutaneously once weekly for 4 weeks. Subsequent cycles may be initiated based on clinical response, with at least one week between cycles; the safety and efficacy of initiating subsequent cycles more frequently than every 6 weeks have not been established.. The standard adult dose of VYVGART is: 10 mg/kg intravenously over 1 hour, once weekly for 4 weeks (4 doses total), then 10 mg/kg intravenously over 1 hour every 2 weeks starting at week 5.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VYVGART HYTRULO and VYVGART in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VYVGART HYTRULO is classified as Category C. VYVGART HYTRULO (efgartigimod alfa and hyaluronidase) is a neonatal Fc receptor antagonist. There are no adequate human data on use in pregnant women to inform a drug-associated ri. VYVGART is classified as Category C. VYVGART (efgartigimod alfa) is an IgG1 antibody fragment. As a large protein, it is not expected to cross the placenta significantly in the first trimester, but placental transfer . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Efgartigimod alfa is expected to be degraded into small peptides and amino acids via general protein catabolism; hyaluronidase is metabolized locally.
Metabolized by catabolic pathways into small peptides and amino acids.
Efgartigimod alfa, the active component, is a human Ig G1 antibody fragment; it is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific renal or biliary excretion studies are available; as an antibody fragment, it is not excreted renally intact. Hyaluronidase (recombinant human) is locally degraded and does not contribute to systemic excretion.
Efgartigimod alfa is catabolized by general protein degradation pathways; no renal or biliary excretion of intact drug. Less than 1% of the dose is excreted unchanged in urine.
Efgartigimod alfa is a monoclonal antibody fragment; serum protein binding is negligible (<5%). No specific binding proteins identified.
Efgartigimod alfa is a human Ig G1 antibody fragment; as a protein, it is not bound to plasma proteins in a conventional sense. It is present in plasma as free monoclonal antibody.
Vd is approximately 150 m L/kg (0.15 L/kg), consistent with limited extravascular distribution, primarily confined to plasma and interstitial space.
Volume of distribution is approximately 0.3-0.4 L/kg, indicating distribution primarily within the vascular space and limited extravascular penetration.
Following subcutaneous administration of VYVGART HYTRULO, the absolute bioavailability of efgartigimod alfa is approximately 70% (range 55-85%) compared to intravenous administration.
Administered intravenously; bioavailability is 100% by the IV route. No other routes are clinically relevant.
No formal studies have been conducted in patients with hepatic impairment. Efgartigimod alfa is degraded into small peptides and amino acids, and hepatic impairment is not expected to significantly affect its clearance. No dose adjustment is recommended for patients with mild to moderate hepatic impairment (Child-Pugh class A or B). Use in severe hepatic impairment (Child-Pugh class C) has not been studied.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not studied in moderate or severe hepatic impairment (Child-Pugh class B or C); use not recommended.
Safety and effectiveness in pediatric patients have not been established. VYVGART HYTRULO is not approved for use in pediatric patients.
Not approved for pediatric patients (safety and efficacy not established for children < 18 years).
No dose adjustment is required in geriatric patients (≥65 years of age). Clinical studies included a limited number of patients aged 65 and older; no overall differences in safety or efficacy were observed between elderly and younger adult patients.
No specific dose adjustment required for geriatric patients (>= 65 years) based on population pharmacokinetic analysis; monitor for adverse reactions due to potential age-related comorbidities and polypharmacy.
No black box warning.
History of severe hypersensitivity to efgartigimod alfa or any excipient.
No specific food interactions have been identified with efgartigimod alfa and hyaluronidase. Avoid alcohol consumption due to potential exacerbation of myasthenia gravis symptoms. Maintain adequate hydration. No grapefruit juice interaction known.
No known food interactions. No dietary restrictions required.
VYVGART (efgartigimod alfa) is an Ig G1 antibody fragment. As a large protein, it is not expected to cross the placenta significantly in the first trimester, but placental transfer increases in the second and third trimesters. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in monkeys at exposures up to 16 times the human clinical exposure. However, due to Fc Rn inhibition, potential risks include fetal hypogammaglobulinemia and reduced passive immunity transfer. Caution is advised in the second and third trimesters.
There are no data on the presence of efgartigimod alfa or hyaluronidase in human milk, effects on the breastfed infant, or effects on milk production. Efgartigimod alfa is a large monoclonal antibody (molecular weight ~147 k Da) and is likely to be present in human milk in low amounts, especially with maternal Ig G degradation. The M/P ratio is unknown. Because of the potential for adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment and for 21 days after the last dose.
It is unknown if efgartigimod alfa is excreted in human milk. However, as a protein (Ig G1 fragment), it is likely present in low amounts. The M/P ratio is not determined. Efgartigimod alfa has a molecular weight of ~51 k Da and may undergo gastrointestinal digestion in the infant. Given its mechanism (Fc Rn inhibition), potential for accumulation is low. Consider benefits of breastfeeding, mother's need for VYVGART, and potential risk to the infant. No specific lactation data available.
No specific dose adjustments are recommended for VYVGART HYTRULO during pregnancy. Pharmacokinetic changes typical of pregnancy (increased plasma volume, enhanced clearance) may alter drug exposure; however, efgartigimod alfa is a monoclonal antibody cleared by target-mediated elimination and neonatal Fc receptor (Fc Rn) binding. Pregnancy may alter Fc Rn function, potentially affecting drug clearance, but data are insufficient to recommend a dose adjustment. The recommended dosing regimen (weekly subcutaneous injections) should be maintained unless otherwise indicated by maternal safety or clinical response. Monitor clinical response and consider adjusting if efficacy is reduced, but no formal pharmacokinetic-based dose adjustments are established.
No dose adjustments are recommended based on pharmacokinetic changes in pregnancy. There are no data on altered clearance or distribution of efgartigimod alfa in pregnant women. However, pregnancy-associated physiological changes (increased plasma volume, altered protein binding) may affect exposure; but data are insufficient to recommend specific adjustments. Dose should be based on body weight and clinical response. No dose adjustments required in pregnancy based on available pharmacokinetic data.
Wash hands before and after injection. Rotate injection sites on the abdomen (avoid navel area).,Report signs of infection (fever, chills, cough) or hypersensitivity (rash, itching, swelling) promptly.,Do not receive live vaccines (e.g., MMR, yellow fever, varicella) during treatment.,Inform your doctor if you have hepatitis B or tuberculosis, or if you are pregnant, breastfeeding, or planning to become pregnant.,Store the autoinjector or syringe in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze. Bring to room temperature before injection (15-25 minutes).
This medicine lowers antibody levels to improve muscle weakness.,You will receive IV infusions once weekly for 4 weeks per cycle.,Report any signs of infection (fever, sore throat, cough) immediately.,Avoid live vaccines during treatment.,Tell your doctor if you are pregnant or breastfeeding.